Highlights of news on TP Therapeutics, Inc.

Turning Point Therapeutics Appoints Jacob Chacko, M.D., to its Board of Directors

TP Therapeutics and Almac Diagnostic Services Enter into Agreement to Develop Next-Generation Sequencing Pan-Cancer Companion Diagnostic

TP Therapeutics Completes $80 Million Mezzanine Financing Co-Led by Foresite Capital and venBio Partners

OncLive report on Repotrectinib: “Repotrectinib Shows Promising Activity in ROS1+ NSCLC”

Press release: “TP Therapeutics Announces Updated Interim Phase 1/2 Clinical Trial Data of Repotrectinib (TPX-0005) in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer Patients at 19th World Conference on Lung Cancer”

Press release: “TP Therapeutics Announces Updated Interim Phase 1 Data with Repotrectinib (TPX-0005) in ROS1 Fusion-positive NSCLC to be Presented at World Conference on Lung Cancer”

Press release: “Cancer Discovery Highlights Potent Effects of TP Therapeutics’ Novel, Lead Investigational Compound Repotrectinib in Tumors Harboring ROS1, TRK or ALK Fusions with Solvent Front Mutations”

Press release: “TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TPX-0005 at ASCO 2018: Data Presented from the Ongoing TRIDENT-1 Study”

Press release: “TP Therapeutics Announces Phase 1 Data of TPX-0005 to be Presented at the Annual American Society of Clinical Oncology Meeting”

Press release: “TP Therapeutics Appoints Athena Countouriotis, M.D., as EVP and Chief Medical Officer”

Press release: “TP Therapeutics Appoints Lewis Shuster to Board of Directors”

Press release: “TP Therapeutics Appoints Sheila K. Gujrathi, MD to Board of Directors and as a Strategic Advisor”

Press release: “TP Therapeutics Announces FDA Orphan Drug Designation Granted to TPX-0005 for Treatment of Non-Small Cell Lung Adenocarcinomas Harboring ALK, ROS1, or NTRK Oncogenic Rearrangements”

FierceBiotech “Cancer Resistance Firm Reaps $45M in Third Round”

Press release: “TP Therapeutics Closes $45M Series C Financing”

San Diego Business Journal “TP Therapeutics Raises Nearly $18 Million in Series B Financing Round”